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Abstract
Background: Multi-drug Resistance associated Protein-1 (MRP1) can export chemotherapeutics from cancer cells
and is implicated in chemoresistance, particularly as is it known to be up-regulated by chemotherapeutics. Our aims
in this study were to determine whether activation of Notch signalling is responsible for chemotherapy-induced MRP1
expression Notch in breast cancers, and whether this pathway can be manipulated with an inhibitor of Notch activity.
Methods: MRP1 and Notch1 were investigated in 29 patients treated with neoadjuvant chemotherapy (NAC) for breast
cancer, using immunohistochemistry on matched biopsy (pre-NAC) and surgical samples (post-NAC). Breast epithelial
cell cultures (T47D, HB2) were treated with doxorubicin in the presence and absence of functional Notch1, and qPCR,
siRNA, Western blots, ELISAs and flow-cytometry were used to establish interactions.
Results: In clinical samples, Notch1 was activated by neoadjuvant chemotherapy (Wilcoxon signed-rank p < 0.0001)
and this correlated with induction of MRP1 expression (rho = 0.6 p = 0.0008). In breast cell lines, doxorubicin induced
MRP1 expression and function (non-linear regression p < 0.004). In the breast cancer line T47D, doxorubicin activated
Notch1 and, critically, inhibition of Notch1 activation with the γ-secretase inhibitor DAPT abolished the doxorubicin-
induced increase in MRP1 expression and function (t-test p < 0.05), resulting in enhanced cellular retention of doxorubicin
and increased doxorubicin-induced apoptosis (t-test p = 0.0002). In HB2 cells, an immortal but non-cancer derived breast
cell line, Notch1-independent MRP1 induction was noted and DAPT did not enhance doxorubicin-induced apoptosis.
Conclusions: Notch inhibitors may have potential in sensitizing breast cancer cells to chemotherapeutics and therefore
in tackling chemoresistance.
Background
Therapy for primary breast cancer usually involves
tumour resection combined with radiotherapy, endocrine-
therapy, and/or chemotherapy. Approximately 30 % of
patients receive chemotherapy, typically including anthra-
cyclines and/or taxanes [1]. However, resistance to chemo-
therapy is a substantial problem, reflected in subsequent
presentations with recurrences. An important research
goal in breast cancer is to understand better the molecular
mechanisms that lead to failure of chemotherapy
treatment regimens [2]. ATP-binding cassette (ABC) pro-
teins are a family of xenobiotic drug transporters many of
which are capable of exporting chemotherapeutic drugs
from cells. Accordingly, some ABC proteins have been im-
plicated in chemotherapy resistance. For example, Multi-
drug Resistance associated Protein-1 (MRP1; encoded by
the gene ABCC1) can export the chemotherapeutics epir-
ubicin and doxorubicin [3, 4], and is overexpressed in a
variety of multi-drug resistant cancer cell lines [5, 6]. Fur-
thermore, MRP1 expression has been linked with poor
clinical outcomes in breast cancer [7–9], although this
correlation has not been observed consistently in all such
studies [10], perhaps due to lack of statistical power. Vari-
ous small molecule inhibitors of ABCs have been developed
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as potential sensitizing agents for chemotherapy, yet these
have not progressed from trials to clinic largely because
they are not well tolerated in normal cells, particularly of
the liver, kidneys and intestine [11]. Elucidation and
targeting of tumour specific pathways that regulate
expression of ABCs may present methods to inhibit
ABC function in cancer cells, thereby sensitizing them
to chemotherapy agents, while reducing side effects
associated with unwanted influences in normal cells.
The work described here has linked two independent
published studies to suggest a potential cancer-specific
regulatory pathway for MRP1. First, MRP1 was shown
to be a direct transcriptional target of Notch1 in the
multi-drug resistant breast cancer cell line, MCF7-VP
[12]. Secondly, Notch signalling was shown to be signifi-
cantly up-regulated in breast tumours of patients treated
with neoadjuvant chemotherapy (NAC) [13]. Based on
these observations, our hypothesis was that in some
breast cancers chemotherapy drives MRP1-dependent
acquired resistance via Notch signalling.
Notch molecules are a family of four (Notch1 to 4)
signalling molecules that can act as transcriptional co-
regulators; Notch1 is implicated in mammary gland
development [14], breast cancer [15–17] and chemore-
sistance to doxorubicin [18]. Notch proteins are initially
expressed as trans-membrane receptors at the plasma
membrane. When activated by an extracellular ligand
(for example Jagged or Delta), Notch1 undergoes a
sequence of proteolytic cleavages, mediated by ADAM
proteins and the γ-secretase complex, releasing an intra-
cellular domain, Notch1IC. NotchIC translocates to the
nucleus and acts as a transcriptional co-regulator at a
wide range of target genes [19]. Inhibitors that act at dif-
ferent stages of this activation cascade have been devel-
oped with a view to their potential use as therapeutics
[20]. Of these, inhibitors of γ-secretase were developed
first and are the most studied in terms of clinical trials
for both Alzheimer’s disease [21, 22] and cancer [23],
although they have proved to have problematic toxicity
profiles in both contexts. The identification of new
Notch inhibiting compounds with greater tolerability
however promises further research into their use as anti-
cancer agents in the future [24]. Here, we have explored
the interplay between chemotherapy, Notch signalling,
and expression and function of MRP1 in breast cancer,
with a view to determining whether Notch inhibitors
could play a role in reducing acquired chemotherapy
resistance mediated by MRP1.
Methods
Patient selection and ethical approval
Ethical approval for use of patient samples and anon-
ymised data was obtained from Leeds (East) Research
Ethics Committee (06/Q1206/180) – written informed
consent was taken from patients in accordance with this
approval. The work complies with the Helsinki Declar-
ation. Patients receiving NAC for primary breast cancer
at LTH NHS Trust from 2005 to 2009 were identified.
Cases to be studied further were selected to limit
tumour heterogeneity. Inclusion criteria were: >3 years
clinical follow-up after NAC; post-operative radiother-
apy; grade 2 or 3 invasive ductal carcinoma on core
biopsy; NAC regimen of anthracyclines +/- taxanes;
matching pairs of biopsy and resection blocks available.
Exclusion criteria were: inflammatory breast carcinoma;
adjuvant chemotherapy in addition to NAC. Twenty-
nine patients were identified for analysis. Patient and
clinico-pathological characteristics were also collected
(Table 1). Note that this cohort is a subset of a cohort
analysed by us previously in relation to BCRP, Pgp and
MRP1 expression [10].
Immunohistochemistry
Immunohistochemistry was performed as described pre-
viously [10]. In summary, 5 μm sections were taken, and
for each case matched biopsy and resection samples
were placed on the same single slide (SuperFrost Plus;
Menzel-Glaser, Braunschweig, Germany) to allow direct
comparisons of staining between biopsy and resection.
Slides were air-dried, and samples dewaxed with xylene
and submerged in ethanol. Epitopes were retrieved by
heat (900 W microwave, 10 min) in 10 mM citrate buf-
fer (pH 6.0) and endogenous peroxidase activity was
blocked using 0.3 % H2O2 (10 min). For anti-activated
Notch1, non-specific primary antibody binding was
blocked using casein (SP5020; Vector, Burlingame, USA)
diluted 10-fold in antibody diluent reagent (Invitrogen,
Carlsbad, USA) for 20 min. Slides were stained with the
following primary antibodies in antibody diluent reagent
for 1 h at room temperature; MRP1 (1:50, QCRL1 clone;
sc18835, Santa Cruz Biotech, Santa Cruz, USA); activated
Notch1 (Notch1IC: 1:100; ab8925, Abcam, Cambridge,
UK). Both antibodies have been used previously for
immunohistochemistry on breast tissue [25, 10], and for
western blots with breast cell lines [26, 27]. Immuno-
staining was visualised using Envision reagents (Dako,
Gostrup, Denmark). Sections were counter-stained with
Mayer’s haematoxylin and mounted in DPX (Fluka,
Gillingham, UK). MRP1 expression was quantified
using computer-aided scoring as a histoscore from 0
(no staining) to 300 (strong staining throughout epithelial
areas) as described previously [10]. Notch1IC nuclear
staining was scored manually by two independent scorers
(BK, BJW) using the Allred method [28, 29], giving scores
from 0 (no staining) to 8 (strong staining in >66 % of
tumour cells). Weighted Kappa coefficients (k) for the two
independent scores were 0.78 for biopsies (good agree-
ment), and 0.9 for resections (near perfect agreement);
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overall k = 0.89 (n = 58). Averages of the two scores were
used as final expression scores.
Cell Culture, transfection and drug treatments
Cell lines were obtained originally from the European
Collection of Animal Cell Cultures. Cell line identities
were confirmed (STR profiles, Leeds Genomics Service)
and lines were consistently negative for mycoplasma
(MycoAlert Mycoplasma detection assay, Lonza, Basal,
Switzerland). Cells were maintained in DMEM supple-
mented with 10 % FCS (reagents from Invitrogen, Carlsbad,
USA). Cells were seeded at either 1x105 (HB2) or 2.5x105
(other lines) cells/well in 6-well plates and left overnight
before experiments unless otherwise stated. Trisilencer-27
siRNAs against Notch1-4 and scrambled controls were
obtained from Origene (SR303207, SR303209, SR303210,
SR303211, SR30004, Austin, USA). For transfection, cells
were plated in 24-well plates and incubated overnight (to
reach ~50 % confluence). Transfection was performed with
10nM siRNA with RNAiMAX (13778030, Invitrogen,
Carlsbad, USA) in optimem for HB2 or Interferrin (409-10
Polyplus, Source Bioscience, Nottingham, UK) in DMEM
for T47D according to the manufacturer’s protocols. Fresh
medium was added after 6 h (HB2) or 24 h (T47D) and
cells were harvested 72 h post-transfection. Drug stocks
were stored in DMSO at -20 °C at 10 mM for doxorubicin
hydrochloride (obtained from Leeds Hospital Teaching
Trust), 1 mM for Calcein-AM (17783, Sigma, Poole, UK),
or at 100 mM for DAPT (D5942, Sigma, Poole, UK) and
MK571 (BMLRA1090005, Enzo Life Sciences, Exeter, UK).
Vehicle control or drug was applied to cells for 24 h at
1 μM doxorubicin, 50 μM DAPT, 25 μM MK571 and
0.5 μM Calcein-AM unless otherwise stated.
qPCR and western blots
For RNA analyses, mRNA was extracted using ReliaPrep
with on-column DNase according to manufacturer’s in-
structions (Promega, Madison, USA). cDNA was synthe-
sized using 500 ng RNA, GoScript and random primers
(Promega, Madison, USA). Single RTs were performed
for each sample and were assessed in duplicate wells by
qPCR using SYBR green (Promega, Madison, USA) on
an Applied Biosystems 7500 thermal cycler. Primers
were designed using primer express v3 and sequences
were (5’ to 3’): hβACTIN-F TTCTACAATGAGCTGC
GTGTG, hβACTIN-R GGGGTGTTGAAGGTCTCAAA,
hABCC1-F GGGACTCAGGAGCACACGAA, hABCC1-
R AAATGCCCAGGGCTCCAT, hHES1-F AGGCGGA-
CATTCTGGAAATG, hHES1-R CGGTACTTCCCCAG-
CACACTT, hHEY1-F GAAACTTGAGTTCGGCTCTA
GG, hHEY1-R GCTTAGCAGATCCTTGCTCCAT, hNO
TCH1-F GTCAACGCCGTAGATGACC, hNOTCH1-R
TTGTTAGCCCCGTTCTTCAG. Quantification was per-
formed using the ΔΔCT method [formula 2^-(treated cT
target-gene – βactin)/(vehicle control cT target-gene –
βactin)]. RT- and water only reactions were included and
were essentially undetectable for all primer sets. For pro-
tein analyses, cells were lysed in RIPA buffer with protease
inhibitor cocktail (Sigma, Poole, UK) and 10 mM PMSF.
25 μg protein was mixed with Laemmli buffer and heated
(no heating for MRP1) before SDS-PAGE (4–15 % pre-
cast polyacrylamide gels; Invitrogen, Carlsbad, USA).
Table 1 Clinico-pathological features of the patient cohort
Characteristic Categories No. of patients (%)
n = 29
Age <45 12 (41.4)
>45 17 (58.6)
Grade (pre-NAC) 2 9 (31)
3 20 (69)
Stage (pre-NAC) T2 19 (65.5)
T3 10 (34.5)
MRI response Minimal 9 (31)
Partial 20 (69)
NAC regimen Epirubicin + cyclophosphamide (EC) 5 (17.2)
EC + taxanes 24 (82.8)
Lymphovascular invasion Positive 11 (37.9)
Axillary metastasis Positive 15 (51.7)
Oestrogen receptor Positive 17 (58.6)
Her2 Positive 3 (10.3)
Surgery Breast conserving 11 (37.9 %)
Mastectomy 18 (62.1 %)
Kim et al. BMC Cancer  (2015) 15:634 Page 3 of 12
Samples were transferred to PVDF, blocked with 5 %
milk/TBS-T and incubated with primary antibodies, anti-
MRP1 (1/2000, MRPr1, ab83368, Abcam, Cambridge, UK)
or anti-GAPDH (1/10,000, G9545, Sigma, Poole, UK)
overnight (4 °C). Bound antibodies were detected with ap-
propriate HRP conjugated secondary antibodies (1/2000,
Dako, Gostrup, Denmark) and visualized with West-Pico
or West-Femto diluted 1/5 with West-Pico (Pierce, Rock-
ford, USA). Densitomtery was performed in ImageJ v1.47
and MRP1 values normalised to GAPDH and vehicle
treated control.
Enzyme-Linked ImmunoSorbent Assays (ELISAs)
Cells were plated in T25 flasks 24 h prior to treatments.
Drugs were applied as described above and cells har-
vested after 24 h. Proteins were prepared and ELISA
(Cleaved Notch1 cat. no. 7194; Cell Signalling, Beverly,
USA) performed according to manufacturer’s protocols.
Colorimetric readings were made at 450nM on an Opsis
MR microplate reader (Dynex-Magellan, VA, USA) with
Revelation quick-link software.
Calcein-AM and doxorubicin retention assays
For Calcein-AM: 1x106 cells were plated in T25 flasks
and left overnight to adhere. Doxorubicin and DAPT
were added at final concentrations of 1 μM and 50 μM
respectively and left for 24 h. Where indicated, MK571
was added at 25 μM final concentration for 20 min.
Cells were trypsinised, washed in PBS, suspended in
complete RPMI and incubated in suspension in FACS
tubes at 37 °C for 30 min. Cells were then loaded with
Calcein-AM (0.2 μM final concentration) for 1 h at 37 °C.
For washout, cells were washed in PBS three times and
resuspended in complete RPMI. For analysis, cells were
pelleted and resuspended in phenol-red free RPMI with
2 % FCS. 7AAD was added according to manufacturer’s
recommendations. Flow cytometry for Calcein was per-
formed using a LSRII Flow Cytometer (BD Bioscience,
Franklin Lakes, USA) - 488 nm laser, 505 nm LP dichroic
mirror and 530/30 nm bandpass filter with appropriate
compensation to address any spillover from doxorubicin
fluorescence (assessed using 550 nm LP dichroic mirror
and 575/26 nm bandpass filter). For doxorubicin retention
assays, cells were treated with either 50 μM DAPT, 25 μM
MK571 or vehicle control for 24 h and then exposed to
a repeat dose of DAPT, MK571 or vehicle control in
the presence or absence of doxorubicin (1 μM) for 4 h.
Cells were trypsinised and resuspended in phenol-red
free RPMI with 1 % FCS. Flow cytomtery was per-
formed using an Attune NxT Acoustic Focusing Imager
(Life Technologies) and fluorescence was measured in
the BL3 channel.
Apoptosis assays
Cells were either treated with 1 μM DAPT (or vehicle
control) for 24 h and then exposed to vehicle control,
and a second DAPT treatment (1 μM) in the presence
or absence of doxorubicin (10nM). Cells were trypsinised,
washed in PBS and incubated with Annexin V-FITC and
PI according to manufacturers recommendations (556547,
BD Biosciences, Oxford, UK) for 1 h. Cells were analysed
by flow cytometry using a LSRII Flow Cytometer (BD Bio-
science, Franklin Lakes, USA). Cells positive for Annexin
V, PI or both were classified as apoptotic.
Results
MRP1 and Notch1IC are up-regulated in breast cancers by
chemotherapy
In order to assess the relevance of MRP1 expression and
Notch signalling in chemotherapy treatment, the expres-
sion levels of MRP1 and activated Notch1, Notch1IC,
were examined using immunohistochemistry in tumours
from 29 breast patients treated with NAC. Clinical and
pathological features of this cohort are shown in Table 1.
Expression was examined both pre-NAC, using diagnostic
biopsies, and post-NAC, using matched surgical resec-
tions. Representative staining patterns for each antigen are
shown (Fig. 1) and staining was quantified (Fig. 2). MRP1
and Notch1IC were absent or expressed at very low levels
prior to NAC, while positive expression of both was typ-
ical post-NAC, although with considerable variation in
levels between tumours. Expression of MRP1 or Notch1IC
did not significantly correlate with any of the clinical or
pathological features listed in Table 1 (although it should
be noted that this analysis is limited by the relatively small
cohort size). However, both MRP1 and NotchIC were sig-
nificantly up-regulated after NAC (Wilcoxon signed-rank
test p < 0.0001; Fig. 2b), and their expressions were signifi-
cantly positively associated post-NAC (rho coefficient 0.6,
p = 0.0008), but not prior to treatment (Fig. 2c). We
concluded that our data were compatible with Notch1
signalling playing a role in chemotherapy-induced up-
regulation of MRP1 expression.
Doxorubicin induces Notch targets and MRP1 in breast
cell lines
To determine whether Notch-dependent regulation of
MRP1 could be demonstrated in vitro, two breast cell
lines were used: the ER positive cancer line T47D along-
side the non-malignant but immortalised HB2 line. Cell
lines were treated with the anthracycline doxorubicin, or
with vehicle control, for 24 h and MRP1 expression was
examined by qPCR and western blotting (Fig. 3a). MRP1
expression was increased after doxorubicin addition in
both cell types. In addition, expression of the well-
established Notch target genes Hes1 and Hey1 were
found to be induced after exposure to doxorubicin
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(Fig. 3b), consistent with activation of Notch signalling.
MRP1, Hes1 and Hey1 expression were all also increased
after doxorubicin treatment in the MCF7 breast cancer
cell line (Additional file 1: Figure S1). MRP1 activity was
assessed by quantification of the export of the fluorescent
MRP1 substrate esterified calcein using flow-cytometry.
T47D or HB2 cells were treated with doxorubicin or con-
trol as before, and were then loaded with the dye. Intracel-
lular levels of esterified calcein were assessed hourly after
the dye was removed from the medium (Fig. 3c). In both
cell lines, doxorubicin treated cells exported calcein sig-
nificantly more efficiently than the controls (non-linear
regression: T47D p = 0.0035; HB2 p = 0.0009), although
these differences were relatively small. We concluded
that doxorubicin induced MRP1 expression and activity
in both cell lines.
Doxorubicin induces Notch1 activation and Notch-
dependent activation of MRP1 in T47Ds but not HB2s
Next, we aimed to determine whether this MRP1 up-
regulation was susceptible to therapeutic intervention by
inhibiting Notch function. The γ-secretase inhibitor
DAPT was used to prevent cleavage and functional acti-
vation of Notch [30]. T47D or HB2 cells were treated
with vehicle control, DAPT, doxorubicin or a combin-
ation of doxorubicin and DAPT. Notch1 activity was
assessed directly using ELISAs for Notch1IC while MRP1
expression was assessed using qPCR (Fig. 4). In T47D
cells, DAPT reduced basal Notch1 activity as expected,
while doxorubicin induced Notch1 activity. In the com-
bination treatment, DAPT completely inhibited the
doxorubicin-induced increase in Notch1 activity (top left
panel). This was associated with similar changes in
MRP1 expression (top right panel): DAPT reduced basal
MRP1 levels and, critically, blocked doxorubicin-induced
MRP1 expression. These data support the conclusion
that doxorubicin drives a Notch1-dependent increase in
MRP1 expression and that this increase can be inhibited
by DAPT. The result was less clear-cut in HB2 cells
(bottom panels). DAPT reduced Notch1 activity as ex-
pected, but there was no evidence for doxorubicin indu-
cing Notch1 activity in this cell line, despite the previous
observation of Hey1/Hes1 induction (Fig. 3b). Further-
more, DAPT had no impact on basal MRP1 expression.
However, doxorubicin did induce MRP1 expression, and
this induction demonstrated a trend to be reduced by
DAPT (not significant). These data support Notch1-
independent actions on MRP1 expression by doxorubi-
cin, as MRP1 expression increased in the absence of an
increase in Notch1 activity.
With the potential role of other γ-secretase targets in
mind, we then sought to confirm the role of Notch1 in
controlling MRP1 levels using siRNA approaches. T47D
or HB2 cells were transfected with siRNAs against each
Fig. 1 Representative staining patterns of MRP1 and Notch1IC in matched breast tumour tissues pre- and post-NAC. Immunohistochemistry was
performed on matched tissues from pre-NAC diagnostic core biopsies (left) and post-NAC surgical resection samples (right) for either MRP1 or
activated Notch1 as labelled
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of Notch1-4, and we examined whether this reduction in
basal activity of these Notch molecules would impact on
MRP1 expression using qPCR (Fig. 5). Targeting of
Notch1, but not the other Notch molecules, reduced
MRP1 expression in T47D cells (left top panel), but not
in HB2 cells (left bottom panel). As a control, we also
confirmed that Notch1 siRNAs had indeed successfully
reduced Notch1 expression in both cell lines (right
panels). These data further support the conclusion that
MRP1 expression is dependent on Notch1 in T47D cells
but not in HB2 cells.
Inhibition of Notch activation reduces doxorubicin-induced
MRP1 activity in T47Ds but not HB2s
Next, we assessed whether the changes in MRP1 expres-
sion associated with doxorubicin and/or DAPT treat-
ment are reflected in changes in export activity and
subsequent cell survival. MRP1 substrate-export activity
was tested using the calcein loading assay as previously,
and in addition we used the natural fluorescence of
doxorubicin as a further measure of cellular export
potential. For calcein assays, we present the relative
amounts of fluorescent dye remaining in cells after
Fig. 2 MRP1 and Notch1IC are induced by NAC in breast cancer patients and their expression is significantly positively associated post-NAC.
Immunohistochemistry for either MRP1 or activated Notch1 was performed and quantified on matched pre- and post-NAC breast cancer tissues
from 29 patients. a Expression of MRP1 (top) and Notch1IC (bottom) is shown for each individual patient (each black line) both pre- and post-NAC. b
Expression of MRP1 and Notch1IC across the cohort as box and whisker plots showing median (line), 25th-75th percentile (box) and min to
max values (whiskers). Wilcoxon ranked score, p < 0.0001 for both MRP1 and Notch1IC. c A scatter plot of MRP1 and Notch1IC expression with
post-NAC demonstrating a significant positive correlation (rho coefficient 0.5884, p = 0.0008)
Kim et al. BMC Cancer  (2015) 15:634 Page 6 of 12
5 hours wash-out of calcein-AM from the medium -
greater MRP1 activity leads to more dye export and
lower levels of cellular fluorescence (Fig. 6a and d). In
doxorubicin assays, efflux potential is presented as rela-
tive amount of intra-cellular doxorubicin (Fig. 6b and e).
For both assays, we have included a further control,
MK571, which is a chemical inhibitor of MRP1 function
and represents the maximal increases in fluorescence
that can be achieved by functional inhibition of MRP1.
In T47D cells, treatment with DAPT significantly
increased calcein retention (reflecting reduced MRP1 ac-
tivity), while treatment with doxorubicin reduced calcein
Fig. 3 MRP1 expression and function are induced in breast cell lines by doxorubicin in vitro. HB2 or T47D cells were treated for 24 h with 1 μM
doxorubicin or vehicle control (DMSO). a MRP1 expression was quantified by qPCR (left) or Western blot (right). For qPCR, means with SD of
triplicate PCR reactions are presented. Densitometry values are presented beneath MRP1 blots and pertain to the blots presented. Data for qPCR
and Western blot are representative of at least 2 independent biological replicates. b Expression of canonical Notch target genes Hes1 and Hey1
was quantified by qPCR. Means are presented with SD of triplicate PCR reactions, and experiments are representative of at least 2 biological
repeats. c Efflux of the fluorescent MRP1-substrate, esterified calcein, was assessed using flow-cytometry. Efflux was significantly enhanced in the
presence of doxorubicin (non-linear regression T47D p = 0.0035, HB2 p = 0.0009). Analysis of individual timepoints reveal T47D cells show significantly
enhanced efflux over 2-5 h post-wash out (two-tailed t-test p < 0.05 at each time point), whilst significant efflux occurred from 4 to 5 h post-wash out
for HB2 cells (two-tailed t-test p < 0.01 at 4 h and p < 0.0001 at 5 h). The mean response of 4 independent biological replicates with technical triplicates
is presented. Error bars represent the SEM of the 4 replicates
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retention (reflecting increased MRP1 activity) (Fig. 6a).
Critically, in the combination treatment DAPT abolished
the doxorubicin-induced export of calcein, indeed calcein
was retained to the same degree as after chemical inhib-
ition of MRP1 using MK571, demonstrating that DAPT
was highly-effective at inhibiting MRP1-dependent export
in this context. A similar result was seen when fluores-
cence from doxorubicin itself was assessed (Fig. 6b) –
both DAPT and MK571 induced doxorubicin retention,
again reflecting reduced MRP1 function. We concluded
that DAPT reduces doxorubicin-induced export, thereby
increasing doxorubicin-loading of the cells. To test the
phenotypic effect of this conclusion, Annexin-V/PI assays
were performed to assess apoptosis after the various treat-
ments (Fig. 6c). DAPT had no effect on apoptosis alone,
while doxorubicin – as expected for a chemotherapeutic
agent – induced apoptosis. The combination of DAPT
with doxorubicin caused a larger increase in apoptosis
(Fig. 6c, t-test p = 0.0012) indicating that the DAPT-
induced increase in doxorubicin-loading seen in Fig. 6b
was cytotoxic. These data support the use of the combin-
ation treatment as a potential therapy.
As before, the result in HB2 cells was less clear. Doxorubi-
cin treatment greatly reduced calcein retention and this was
not significantly altered by addition of DAPT (Fig. 6d) – a
result that is compatible with our conclusion from Figs. 4 to
5 that doxorubicin-induced increased expression of MRP1
is likely to be independent of Notch1 signaling in this cell
line. However, more surprisingly, treatment with DAPT
alone significantly increased calcein retention (Fig. 6d), a
finding we can not explain in terms of MRP1 activity since
we previously showed DAPT not to reduce basal MRP1
expression (see Fig. 4). When using doxorubicin fluores-
cence as the marker of export, DAPT caused only a very
slight increase in doxorubicin-loading (Fig. 6e). Finally,
DAPT had no influence on apoptosis either with or without
doxorubicin (Fig. 6f). In HB2 cells, these data demonstrate
that DAPT has some influences on export activity that are
independent of MRP1, and that the combination of doxo-
rubicin and DAPT does not cause synergistic cell killing.
Discussion
MRP1 expression has been studied extensively as a poten-
tial predictor of chemotherapy response and/or clinical
Fig. 4 Doxorubicin-induced expression of MRP1 in T47D cells is abrogated by inhibition of Notch1 activation. Cells were treated for 24 h with
control, 1 μM doxorubicin, 50 μM DAPT (an inhibitor of Notch function) or both in combination. Left: Expression Notch1IC of was determined
using ELISAs. Means with SEM of two independent biological replicates are presented. Right: MRP1 mRNA expression was quantified using qPCR.
Means with SEM of two independent biological replicates are presented. T-tests were used to determine significant changes. * p < 0.05, ** <0.01,
*** < 0.001, ns = not significant
Kim et al. BMC Cancer  (2015) 15:634 Page 8 of 12
outcome in a wide range of cancers [4, 9, 31, 32]. Some
studies demonstrated that high MRP1 expression was as-
sociated with chemotherapy resistance and poor survival,
presumably on account of the ability of MRP1 to export
chemotherapeutics from the tumour cells thereby enhan-
cing their survival. However, previous work from our la-
boratory reported that MRP1 was expressed only at very
low levels in breast cancers prior to chemotherapy and
therefore provided few prognostic or predictive insights
[10]. Interestingly, MRP1 expression in breast tumours
was strongly induced by NAC, specifically implicating up-
regulated MRP1 as a response to therapy and a potential
mediator of the development of acquired resistance. By
identifying and therapeutically targeting the mechanisms
that allow up-regulation of MRP1 it might be possible to
selectively sensitize cancer cells to chemotherapy.
Two published studies, discussed in detail below,
allowed development of the hypothesis that activity of
Notch1 mediates MRP1 induction in some breast cancers.
First, Gonzalez-Angulo et al. compared gene expression
profiles of breast cancers before and after NAC and used
in silico analyses of differences to identify signalling path-
ways influenced by NAC [13]. In the non-basal subset of
tumours, Notch signalling was the most significantly up-
regulated pathway identified, although it should be noted
that this prediction was based solely on bioinformatics
and was not subject to any validation. Secondly, Cho et al.
identified MRP1 as a direct transcriptional target of
Notch1 signalling in an etoposide-resistant variant of the
MCF7 breast cancer cell line, and identified the specific
promoter region allowing Notch1-dependent MRP1 regu-
lation [12]. This regulation was not confirmed in a clinical
setting or related to chemotherapy in this original paper,
although recent support comes from work showing
Notch1-dependent up-regulation of MRP1 to increase
chemo-resistance in stem-like cells from prostate cancer
lines [33]. The data presented herein are based on direct
measures of activated Notch1 and show that Notch signal-
ling is indeed induced by chemotherapy in both clinical
breast cancer (Fig. 2) and breast cell lines (Figs. 3 and 4),
confirming the previous bioinformatic prediction of
Gonzalez-Angulo et al. Furthermore, these data show that
activation of Notch1 at the protein level correlates signifi-
cantly with induction of MRP1 expression (Fig. 2c) and
crucially, confirm clinically the cell line-based findings of
Cho et al. Further clarification of this mechanism was
made by the observation that only Notch1, as opposed to
Notch2-4, regulates MRP1 expression (Fig. 5).
Most importantly, this study investigated whether
chemotherapy-induced MRP1 regulation can be inhib-
ited with potential therapeutics, using a luminal breast
cancer cell line (in accordance with the bias noted by
Gonzalez-Angulo et al. to non-basal cancers) and an
immortalised non-cancer breast epithelial line. Notch
Fig. 5 siRNA knock-down of Notch1 reduces basal expression of MRP1 in T47Ds but not HB2s. Cells were transiently transfected with control or
Notch1, 2, 3 or 4-targetted siRNAs for 72 h. Expression of Notch1 andABCC1/MRP1 was quantified using qPCR and is presented relative to siScrambled
(control) transfected levels. Mean levels from 3 independent siRNAs to each target are presented and results show mean of 2 biological
repeats (error bars represent SEM). T-tests were used to determine significant changes, * p < 0.05, ns = not significant
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regulation of MRP1 has not been investigated in non-
tumouriogenic cells previously. The well-characterised
γ-secretase inhibitor DAPT was used as an inhibitor of
Notch1 activation. γ-secretase inhibitors have a long his-
tory of use in clinical trials for Alzheimer’s disease [34]
and more recently cancer [35–37] including in breast
[38], and their use in combination with chemotherapy
has been proposed previously [39]. Our results demon-
strate differences between the two breast cell lines tested
(see Fig. 7 for a flow-scheme). First, MRP1 and canonical
Notch-targets were induced by doxorubicin in both cell
lines (Fig. 3). However, Notch1 was only activated by this
treatment in the T47D cancer cells and not in the non-
cancer HB2 cells (Fig. 4), and MRP1 induction was
dependent on Notch1 activity only in the cancer cells
(Figs. 4 and 5). These differences were reflected by func-
tional influences of MRP1 both directly at the level of
export of substrates and at the level of induction of
apoptosis by doxorubicin (Fig. 6). In T47D cells, inhib-
ition of Notch activation caused an increased loading of
doxorubicin and enhanced cell killing, while in the non-
cancer HB2 cells this treatment had minimal effects on
doxorubicin loading and no significant effect on cell
killing. It is interesting to note that the combination
treatment enhanced chemotherapy-efficacy in the cancer
cell line, but not in the non-cancer line indicating a po-
tential degree of cancer-specificity that might allow syn-
ergistic killing of the cancer cells while sparing normal
Fig. 6 Inhibition of Notch activation reduces doxorubicin-induced MRP1 function and, in T47D cells, enhances doxorubicin-dependent apoptosis. a
Intracellular calcein levels in T47D cells were quantified 5 h after calcein wash-out following 24 h treatment with control, DAPT (50 μM), doxorubicin
(1 μM), doxorubicin and DAPT, or 0.5 h treatment with the ABC pump-inhibitor MK-571 (25 μM). Data are presented as mean with SEM of 2 biological
replicates. b Intra-cellular doxorubicin levels in T47D cells were quantified after treatment with either doxorubicin alone (1 μM for 4 h), or in
combination with DAPT (pre-treated with 50 μM for 24 h) or MK-571 (pre-treated with 25 μM for 20 min). Data are presented as mean with SEM of 2
biological replicates. c Apoptosis was measured in T47D cells after doxorubicin (10nM for 24 h) and DAPT (1 μM) treatment, alone and in combination.
Data are presented as mean with SEM of 2–4 biological replicates per bar. Asterisks represent significant changes compared to vehicle control or
between test conditions as indicated (two tailed t-test * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant). d-f as described for A-C but in HB2 cells
Fig. 7 Schematic representing the differences between T47D and
HB2 cells following exposure to doxorubicin. Activation of MRP1 and
induction of chemoresistance in T47D cancer cells is Notch1
dependent and can be inhibited by DAPT, representing a potential
chemo-sensitizing strategy. In HB2 cells, doxorubicin induces MRP1
expression but this is independent of Notch1 signalling (1), therefore
Notch inhibitors do not impact on chemo-sensitivity
Kim et al. BMC Cancer  (2015) 15:634 Page 10 of 12
cells, although clearly this remains speculative until con-
firmed in further appropriate models.
Conclusions
We propose that inhibition of Notch signalling may en-
hance the efficacy of chemotherapy for breast cancer
and support the use of Notch inhibitors in clinical trials
testing this hypothesis.
Additional file
Additional file 1: Figure S1. MRP1 expression is induced in MCF7 cells
by doxorubicin in vitro. MCF7 cells were treated for 24 h with 1 μM
doxorubicin or vehicle control (DMSO). A) MRP1 expression was
quantified by qPCR (left) or Western blot (right). For qPCR, means with
SD of triplicate PCR reactions are presented. Densitometry values are
presented beneath MRP1 blots and pertain to the blots presented. Data
for qPCR and Western blot are representative of at least 2 independent
biological replicates. B) Expression of canonical Notch target genes Hes1
and Hey1 was quantified by qPCR. Means are presented with SD of
triplicate PCR reactions, and experiments are representative of at least 2
biological repeats. (TIFF 216 kb)
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